
SXTP Stock Forecast & Price Target
SXTP Analyst Ratings
Bulls say
60 Degrees Pharmaceuticals Inc has demonstrated significant financial growth, with net product revenues soaring by 140% to $607.6k in FY24, and a remarkable 223% year-over-year increase in Q3 FY25, highlighting strong demand for ARAKODA. The continuing sales increase in ARAKODA, which has shown consistent year-over-year growth, positions the company favorably within the specialty pharmaceutical market, reinforcing its potential for sustainable revenue generation. Additionally, the broadening application of Tafenoquine due to its favorable safety profile, combined with rising incidences of diseases like babesiosis, suggests increasing market potential for the company's pipeline products, promising further opportunities for future growth and commercialization.
Bears say
60 Degrees Pharmaceuticals Inc faces a negative outlook primarily due to depressed forward multiples resulting from current market volatility and financial instability characterized by a reported gross loss of approximately $9,000 for Q3 FY24, attributed to a one-time inventory write-off. The company also grapples with low visibility on regulatory approvals for its new indications, posing significant risks of potential dilution from financing options. Additionally, concerns over commercial viability arise from diminishing demand and increased competition in its therapeutic areas, exacerbated by emerging resistance to current treatment strategies and associated tolerability issues that could hinder patient compliance.
This aggregate rating is based on analysts' research of 60 Degrees Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
SXTP Analyst Forecast & Price Prediction
Start investing in SXTP
Order type
Buy in
Order amount
Est. shares
0 shares